MCID: CND004
MIFTS: 56

Candidiasis

Categories: Rare diseases, Infectious diseases, Genetic diseases, Immune diseases, Blood diseases, Skin diseases

Aliases & Classifications for Candidiasis

MalaCards integrated aliases for Candidiasis:

Name: Candidiasis 12 52 3 42 14 69
Systemic Candidiasis 12 50 69
Invasive Candidiasis 50 3 69
Disseminated Candidiasis 12 52
Systemic Candida Infections 50

Classifications:



External Ids:

Disease Ontology 12 DOID:1508
ICD10 33 B37 B37.9
ICD9CM 35 112 112.9
MeSH 42 D002177
NCIt 47 C26711
UMLS 69 C0006840

Summaries for Candidiasis

NIH Rare Diseases : 50 systemic candidiasis includes a spectrum of yeast infections caused by different species (types) of candida. it is a serious infection that can affect the blood, heart, brain, eyes, bones, or other parts of the body. although there are over 200 species of candida, five different species of candida cause 90% of systemic candidiasis. the most common form of this invasive yeast infection is when candida enters the bloodstream (candidemia). signs of candidemia include fever and chills that do not improve with antibiotics. symptoms of other types of systemic candidiasis depend on the organ or system which is infected. systemic candidiasis is the most common fungal infection among hosptilized people in high-income countries, including the united states. diagnosis can be difficult, especially when the candida is not found in the bloodstream. treatment usually includes consists of oral or intravenous (iv) antifungal medications.  last updated: 12/15/2016

MalaCards based summary : Candidiasis, also known as systemic candidiasis, is related to esophageal candidiasis and churg-strauss syndrome. An important gene associated with Candidiasis is AIRE (Autoimmune Regulator), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Fluconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and skin, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 An opportunistic mycosis that involves fungal infection of the mouth, throat, skin, scalp, vagina, fingers, nails, bronchi, lungs, heart and brain by Candida species, of which Candida albicans is the most common. Systemic Candida infections are usually confined to severely immunocompromised persons.

CDC : 3 Photomicrograph of the fungus Candida albicans

Wikipedia : 72 Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Related Diseases for Candidiasis

Diseases in the Candidiasis family:

Candidiasis, Familial, 9 Candidiasis, Familial, 6, Autosomal Dominant
Candidiasis, Familial, 8 Candidiasis, Familial, 2, Autosomal Recessive
Candidiasis, Familial, 3 Candidiasis, Familial, 4, Autosomal Recessive
Familial Candidiasis 5 Familial Candidiasis

Diseases related to Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 298)
id Related Disease Score Top Affiliating Genes
1 esophageal candidiasis 33.5 IFNG IL10 IL17A
2 churg-strauss syndrome 29.5 IFNG IL10 IL17A
3 sclerosing cholangitis 29.3 DEFB4A HTN3 SKAP2
4 lymphoma 28.7 AIRE CD79A IFNG IL10 IL17A
5 vulvovaginal candidiasis 12.4
6 oral candidiasis 12.4
7 chronic mucocutaneous candidiasis 12.3
8 neonatal candidiasis 12.2
9 cutaneous candidiasis 12.1
10 candidiasis, familial, 6, autosomal dominant 12.1
11 candidiasis, familial, 8 12.1
12 candidiasis, familial, 2, autosomal recessive 12.1
13 candidiasis, familial, 4, autosomal recessive 12.1
14 familial candidiasis 12.0
15 candidiasis, familial, 9 12.0
16 autoimmune polyendocrine syndrome type 1 11.8
17 candidiasis, familial, 3 11.7
18 familial candidiasis 5 11.7
19 autoimmune polyendocrinopathy syndrome , type i, with or without reversible metaphyseal dysplasia 11.6
20 candidal paronychia 11.6
21 immunodeficiency 51 11.5
22 immunodeficiency 31c, autosomal dominant 11.5
23 vaginitis 11.2
24 myeloperoxidase deficiency 11.0
25 median rhomboid glossitis 11.0
26 biotinidase deficiency 11.0
27 maturity-onset diabetes of the young, type viii 10.8 CARD9 CLEC7A
28 immunodeficiency 32b, monocyte and dendritic cell deficiency, autosomal recessive 10.8
29 immunodeficiency 42 10.8
30 immunodeficiency-centromeric instability-facial anomalies syndrome-2 10.7 CLEC7A TRAF3IP2
31 vulvovaginitis 10.7
32 laryngotracheitis 10.7 CARD9 CLEC7A
33 gonococcal synovitis 10.7 CARD9 CLEC7A STAT1
34 immunodeficiency 7, tcr-alpha/beta deficient 10.7
35 immunodeficiency with thymoma 10.7
36 severe combined immunodeficiency, x-linked 10.7
37 reticular dysgenesis 10.7
38 immunodeficiency 26, with or without neurologic abnormalities 10.7
39 autoimmune polyendocrine syndrome, type ii 10.7
40 eye accommodation disease 10.6 IFNG IL10
41 neonatal marfan syndrome 10.6 IL17A IL17F
42 neutrophil-specific granule deficiency 10.5 IL10 IL17A
43 intestinal botulism 10.5 CARD9 CLEC7A
44 esophagitis 10.5
45 isolated growth hormone deficiency 10.5 DEFB4A IFNG STAT1
46 dentinogenesis imperfecta 10.4 IFNG IL10 STAT1
47 herpangina 10.4 IFNG IL10 IL17F
48 left bundle branch hemiblock 10.4 IFNG IL10 STAT1
49 acute necrotizing encephalitis 10.4 IFNG IL17A STAT1
50 malignant renovascular hypertension 10.4 CD79A IFNG

Comorbidity relations with Candidiasis via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Chronic Kidney Failure
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Intestinal Obstruction
Paralytic Ileus Protein-Energy Malnutrition
Respiratory Failure

Graphical network of the top 20 diseases related to Candidiasis:



Diseases related to Candidiasis

Symptoms & Phenotypes for Candidiasis

MGI Mouse Phenotypes related to Candidiasis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 AIRE APCS CARD9 CD79A CLEC7A IFNG
2 homeostasis/metabolism MP:0005376 10.03 AIRE APCS CARD9 CD79A CLEC7A IFNG
3 immune system MP:0005387 10.03 IL17RA IL17RC SKAP2 STAT1 TRAF3IP2 AIRE
4 digestive/alimentary MP:0005381 9.97 IFNG IL10 IL17A IL17F STAT1 TRAF3IP2
5 no phenotypic analysis MP:0003012 9.5 AIRE CD79A IFNG IL10 IL17A IL17RA
6 respiratory system MP:0005388 9.23 AIRE CLEC7A IFNG IL10 IL17A IL17F

Drugs & Therapeutics for Candidiasis

Drugs for Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 86386-73-4 3365
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
3
Anidulafungin Approved, Investigational Phase 4,Phase 3,Phase 2 166663-25-8 166548
4
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
5
Micafungin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 235114-32-6 3081921 477468
6
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 18323-44-9 29029
7
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 23593-75-1 2812
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
9
Caspofungin Approved Phase 4,Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
10
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
11
Dequalinium Approved Phase 4 6707-58-0
12
Terconazole Approved Phase 4,Early Phase 1 67915-31-5 441383
13 Castor oil Approved, Vet_approved Phase 4
14
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
15 Racepinephrine Approved Phase 4
16
Nystatin Approved, Vet_approved Phase 4,Phase 3,Phase 2 1400-61-9 11953884
17
Metronidazole Approved Phase 4,Phase 3,Phase 2,Early Phase 1 443-48-1 4173
18
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 1 84625-61-6 55283
19
Ephedrine Approved Phase 4 299-42-3 9294
20
Pseudoephedrine Approved Phase 4 90-82-4 7028
21
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
22
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
23
Mycophenolic acid Approved Phase 4 24280-93-1 446541
24
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
25
Butyric Acid Experimental Phase 4 107-92-6 264
26 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
27 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Steroid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Echinocandins Phase 4,Phase 2,Phase 3,Phase 1
35 Adrenergic Agents Phase 4,Phase 3,Phase 2
36 Adrenergic Agonists Phase 4,Phase 3,Phase 2
37 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 3,Phase 2
38 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2
39 Anti-Allergic Agents Phase 4,Phase 3,Phase 2
40 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
41 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
42 Autonomic Agents Phase 4,Phase 3,Phase 2
43 Bronchodilator Agents Phase 4,Phase 3,Phase 2
44 Dermatologic Agents Phase 4,Phase 3,Phase 2
45
Fluticasone Phase 4,Phase 3,Phase 2 90566-53-3, 80474-14-2 62924 22833648
46 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4,Phase 3
47 glucocorticoids Phase 4,Phase 3,Phase 2
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 282)

id Name Status NCT ID Phase Drugs
1 Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week Unknown status NCT00537888 Phase 4 fluconazole
2 A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in Intensive Care Unit (ICU) Patients Unknown status NCT01734525 Phase 4 Anidulafungin
3 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
4 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
5 Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
6 An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis Completed NCT01769339 Phase 4 Miconazole plus Hydrocortisone
7 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU) Completed NCT00520234 Phase 4 Caspofungin;Normal Saline
8 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
9 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
10 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
11 This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00548262 Phase 4 Anidulafungin;Voriconazole
12 A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush Completed NCT00000951 Phase 4 Fluconazole
13 CRITIC - Treatment of Candidemia and Invasive Candidiasis Completed NCT00670657 Phase 4 AmBisome
14 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
15 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
16 Optimized Radiological Diagnosis of Hepatic Candidiasis During the Treatment of Acute Leukemias Completed NCT01207843 Phase 4
17 Optimal Dosage of Caspofungin in Critically Ill Patients Completed NCT01994096 Phase 4 Caspofungin
18 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
19 Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Completed NCT00388167 Phase 4 Caspofungin
20 Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
21 Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants Completed NCT00001107 Phase 4 Fluconazole;AmBisome
22 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
23 Effectiveness of Hygiene Solutions on Denture Biofilm Completed NCT02407834 Phase 4
24 A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Completed NCT00647907 Phase 4 Voriconazole
25 Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients Completed NCT01495039 Phase 4 Nystatin
26 Micafungin Pharmacokinetics in Obese Patients Completed NCT03102658 Phase 4 Micafungin
27 Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT) Completed NCT02021123 Phase 4 Anidulafungin 100mg single dose iv
28 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
29 Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration Completed NCT02651038 Phase 4 Micafungin
30 Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
31 Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins Completed NCT00839540 Phase 4 micafungin;Micafungin;Caspofungin
32 A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
33 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Recruiting NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
34 Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins Terminated NCT01213823 Phase 4
35 A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia Terminated NCT01982071 Phase 4 Micafungin
36 Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
37 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4 ciclopirox
38 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
39 Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients Withdrawn NCT00304772 Phase 4 Fluconazole;Micafungin
40 RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section Withdrawn NCT02009098 Phase 4 Cefuroxime
41 Fluconazole Versus Micafungin in Neonates With Candidiasis Unknown status NCT02145832 Phase 2, Phase 3 Fluconazole;Micafungin
42 Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
43 Dysbiosis in Localized Provoked Vulvodynia (LPV) Unknown status NCT02393911 Phase 3
44 Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia Unknown status NCT01270490 Phase 3 Interferon-gamma, Recombinant
45 Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight Completed NCT00734539 Phase 3 fluconazole;placebo
46 A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis Completed NCT00128323 Phase 3 Gentian violet 1% solution;Gentian violet 0.00165% solution;Nystatin solution
47 Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis Completed NCT00666185 Phase 3 Micafungin;Fluconazole
48 Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis Completed NCT00665639 Phase 3 micafungin;caspofungin
49 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
50 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole

Search NIH Clinical Center for Candidiasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: candidiasis

Genetic Tests for Candidiasis

Anatomical Context for Candidiasis

MalaCards organs/tissues related to Candidiasis:

39
Brain, Heart, Skin, Tongue, Lung, Bone, Colon

Publications for Candidiasis

Articles related to Candidiasis:

(show top 50) (show all 1876)
id Title Authors Year
1
Assessment of Effectiveness of Fluconazole and Clotrimazole in Treating Oral Candidiasis Patients: A Comparative Study. ( 28462176 )
2017
2
Recurrent vulvovaginal candidiasis. ( 28615397 )
2017
3
A gain-of-function mutation of STAT1: A novel genetic factor contributing to chronic mucocutaneous candidiasis. ( 28597685 )
2017
4
Erythematous Candidiasis. ( 28941670 )
2017
5
Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. ( 28748027 )
2017
6
Oropharyngeal Candidiasis: Fungal Invasion and Epithelial Cell Responses. ( 28081240 )
2017
7
Invasive candidiasis: future directions in non-culture based diagnosis. ( 28829207 )
2017
8
Cutaneous Candidiasis in a Gottingen Minipig: A Potential Pitfall in Preclinical Studies. ( 28929952 )
2017
9
Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation. ( 28815025 )
2017
10
Molecular Identification and Antifungal Susceptibility Pattern of Non-albicans Candida Species Isolated from Vulvovaginal Candidiasis ( 28688376 )
2017
11
Narrow-band imaging can increase the visibility of fibrin caps after bleeding of esophageal varices: a case with extensive esophageal candidiasis. ( 28500570 )
2017
12
Contribution of TLR2 pathway in the pathogenesis of vulvovaginal candidiasis. ( 28911197 )
2017
13
Recurrent vulvovaginal candidiasis. ( 28927765 )
2017
14
Loss of immune control in HIV-infected patients: how does mucosal candidiasis occur? ( 27922753 )
2017
15
Novel solidified reverse micellar solution-based mucoadhesive nano lipid gels encapsulating miconazole nitrate-loaded nanoparticles for improved treatment of oropharyngeal candidiasis. ( 28877639 )
2017
16
Antifungal Prevention of Systemic Candidiasis in Immunocompetent ICU Adults: Systematic Review and Meta-Analysis of Clinical Trials. ( 28857851 )
2017
17
Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis. ( 28088767 )
2017
18
Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital. ( 28511380 )
2017
19
Infection and tissue repair of experimental cutaneous candidiasis in diabetic mice. ( 28604330 )
2017
20
Quantity of Candida Colonies in Saliva: a8"A Diagnostic Evaluation for Oral Candidiasis. ( 28232964 )
2017
21
TNF as marker of oral candidiasis, HSV infection, and mucositis onset during chemotherapy in leukemia patients. ( 28403570 )
2017
22
Characterization of virulence factors of vaginal and anal isolates of Candida albicans sequentially obtained from patients with vulvovaginal candidiasis in north-east Brazil. ( 28844452 )
2017
23
Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. ( 28314677 )
2017
24
External Validation of Risk Prediction Scores for Invasive Candidiasis in a Medical/Surgical Intensive Care Unit: An Observational Study. ( 28904481 )
2017
25
Emergence of Candida glabrata in vulvovaginal candidiasis should be attributed to selective pressure or virulence ability? ( 28730269 )
2017
26
Lasioglossins LLIII affects the morphogenesis of Candida albicans and reduces the duration of experimental vaginal candidiasis in mice. ( 28892177 )
2017
27
Rewiring monocyte glucose metabolism via C-type lectin signaling protects against disseminated candidiasis. ( 28922415 )
2017
28
Early Onset Invasive Candidiasis in Extremely Low Birth Weight Infants: Perinatal Acquisition Predicts Poor Outcome. ( 28077516 )
2017
29
Chronic Mucocutaneous Candidiasis. ( 28065688 )
2017
30
Automatic diagnosis of vulvovaginal candidiasis from Pap smear images. ( 28419509 )
2017
31
CMCD: Chronic Mucocutaneous Candidiasis Disease. ( 28603201 )
2017
32
Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen? ( 28868834 )
2017
33
Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina. ( 28385421 )
2017
34
Elevated nitric oxide in recurrent vulvovaginal candidiasis - association to clinical findings. ( 28052314 )
2017
35
Prevalence of vulvovaginal candidiasis in pregnancy at three health centers in Burkina Faso. ( 28939305 )
2017
36
Vaginal Candida spp. genomes from women with vulvovaginal candidiasis. ( 28582496 )
2017
37
A Novel Heterozygous Mutation in the STAT1 SH2 Domain Causes Chronic Mucocutaneous Candidiasis, Atypically Diverse Infections, Autoimmunity, and Impaired Cytokine Regulation. ( 28348565 )
2017
38
Effectiveness of Ageratina pichinchensis Extract in Patients with Vulvovaginal Candidiasis. A Randomized, Double-Blind, and Controlled Pilot Study. ( 28299831 )
2017
39
Challenges to "Classic" Esophageal Candidiasis: Looks Are Usually Deceiving. ( 28158394 )
2017
40
"Rhetoric to Reality"- Efficacy of Punica Granatum Peel Extract on OralA Candidiasis: An in vitro Study. ( 28274059 )
2017
41
Induction of Severe Chronic Hyperplastic Candidiasis in Rat by Opportunistic Infection of C. albicans through Combination of Diabetes and Intermittent Prednisolone Administration. ( 28830301 )
2017
42
Fungal chorioretinitis with systemic candidiasis in an infant following treatment with broad spectrum antibiotics: A case report. ( 28672927 )
2017
43
Development and Evaluation of Buccal Films Based on Chitosan for the Potential Treatment of Oral Candidiasis. ( 28108973 )
2017
44
New and recurrent STAT1 mutations in seven Chinese patients with chronic mucocutaneous candidiasis. ( 27808400 )
2017
45
Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial. ( 28760590 )
2017
46
Congenital Cutaneous Candidiasis: Prompt Systemic Treatment Is Associated With Improved Outcomes in Neonates. ( 28158439 )
2017
47
Treatment and Prevention of Oral Candidiasis in Elderly Patients. ( 28566666 )
2017
48
Volatile organic compounds in the breath of oral candidiasis patients: a pilot study. ( 28601915 )
2017
49
Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study. ( 28066940 )
2017
50
Recurrent vulvovaginal candidiasis: A review of guideline recommendations. ( 28299777 )
2017

Variations for Candidiasis

Expression for Candidiasis

Search GEO for disease gene expression data for Candidiasis.

Pathways for Candidiasis

Pathways related to Candidiasis according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 CARD9 CD79A CLEC7A DEFB4A HSP90AA1 HTN3
2
Show member pathways
13.21 HSP90AA1 IFNG IL10 IL17A IL17F IL17RA
3
Show member pathways
12.7 HSP90AA1 IFNG IL10 IL17A STAT1
4
Show member pathways
12.44 IFNG IL10 IL17A IL17F STAT1
5
Show member pathways
12.38 HSP90AA1 IFNG IL10 IL17A IL17F STAT1
6 12.29 CARD9 CD79A IFNG IL10 IL17A STAT1
7 12.05 CARD9 CLEC7A IFNG IL10 STAT1
8
Show member pathways
11.99 IFNG IL10 IL17A STAT1
9
Show member pathways
11.76 IFNG IL10 IL17A STAT1
10 11.71 HSP90AA1 IL10 IL17A IL17F STAT1
11 11.64 HSP90AA1 IFNG STAT1
12 11.62 IFNG IL10 IL17A
13 11.58 IFNG IL10 IL17RA
14
Show member pathways
11.56 DEFB4A HSP90AA1 IFNG IL17A IL17F IL17RA
15
Show member pathways
11.52 IL17A IL17F IL17RA IL17RC TRAF3IP2
16
Show member pathways
11.36 IFNG IL17A IL17F IL17RA STAT1

GO Terms for Candidiasis

Cellular components related to Candidiasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 APCS DEFB4A HSP90AA1 HTN3 IFNG IL10

Biological processes related to Candidiasis according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.92 AIRE DEFB4A IFNG IL10 IL17A
2 defense response to bacterium GO:0042742 9.81 DEFB4A HTN3 IFNG IL10
3 humoral immune response GO:0006959 9.65 AIRE IFNG TRAF3IP2
4 chaperone-mediated protein complex assembly GO:0051131 9.56 APCS HSP90AA1
5 negative regulation of growth of symbiont in host GO:0044130 9.55 IFNG IL10
6 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.54 IFNG STAT1
7 positive regulation of interleukin-6 secretion GO:2000778 9.5 IL17A IL17F IL17RC
8 positive regulation of MHC class II biosynthetic process GO:0045348 9.49 IFNG IL10
9 granulocyte chemotaxis GO:0071621 9.46 IL17RA IL17RC
10 defense response to fungus GO:0050832 9.46 HTN3 IL17A IL17RA IL17RC
11 fibroblast activation GO:0072537 9.43 IL17A IL17RA
12 defense response to protozoan GO:0042832 9.43 CLEC7A IFNG IL10
13 regulation of interleukin-6 biosynthetic process GO:0045408 9.4 CARD9 IL17F
14 regulation of interleukin-2 biosynthetic process GO:0045076 9.37 CARD9 IL17F
15 positive regulation of interleukin-23 production GO:0032747 9.13 IFNG IL17A IL17RA
16 positive regulation of cytokine production involved in inflammatory response GO:1900017 8.92 IL17A IL17F IL17RA IL17RC

Molecular functions related to Candidiasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IFNG IL10 IL17A IL17F
2 interleukin-17 receptor activity GO:0030368 8.62 IL17RA IL17RC

Sources for Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....